Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sunitinib in Poorly-differentiated Advanced/Inoperable Neuroendocrine Tumors
NCT01215578Phase 2Terminated
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2008
- Primary completion
- Dec 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in gastroenteropancreatic neuroendocrine tumor (GEP-NET), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Predictive molecular markers of response to sunitinib at 1 year. Started Oct 2008; status: terminated.
02
Drugs
sunitinib
03
Conditions
gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Beyond the preview
Go deeper on NCT01215578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01215578.